STAAR Surgical Company filed a current report on Form 8-K on September 9, 2026, disclosing the appointment of David Bailey as Chief Commercial Officer, effective September 8, 2026, along with the full terms of his compensation arrangement.
Key Highlights
- New appointment: David Bailey was named Chief Commercial Officer of STAAR Surgical Company, effective September 8, 2026.
- Base salary: Bailey will receive an annual base salary of CHF 462,825 (approximately $575,000), prorated in 2026 from his start date.
- Cash bonus target: Bailey is eligible for a fiscal 2026 target bonus of 60% of his base salary, prorated for 2026.
- Initial equity grant: An RSU award valued at $850,000, vesting in equal thirds over three years from the grant date.
- Annual long-term incentive: A 2026 award valued at $1,400,000, prorated from the start date, split 50% stock options and 50% RSUs.
- Prior background: Bailey founded DB Consulting in 2010 and previously served as the company's CEO and President from 2001 to 2008.
STAAR Surgical's Chief Commercial Officer Appointment and Compensation Terms
According to the filing, STAAR Surgical Company (NASDAQ:STAA) announced on September 8, 2026, that David Bailey had been appointed Chief Commercial Officer, effective that same day. The company disclosed that since 2010, Bailey has served as Founder and President of DB Consulting, a Switzerland-based strategic advisory firm providing advice to private equity firms and multinational companies, including STAAR Surgical, on strategic planning, operational improvement, market expansion, return on investment, and product innovation.
The filing further noted that prior to founding DB Consulting, Bailey served as the company's Chief Executive Officer and President from 2001 to 2008, and subsequently as President, International Operations from 2008 to 2011. In connection with his appointment, Bailey executed an Offer Letter, dated September 4, 2026, establishing the terms of his compensation. His annual base salary is set at CHF 462,825, which the filing describes as approximately $575,000, and will be prorated in 2026 based on his start date. He is also eligible to participate in the company's annual cash bonus program, with a fiscal 2026 target bonus equal to 60% of his base salary, prorated for the year.
On the equity side, the filing describes two components. The first is an initial RSU grant valued at $850,000, to be issued on the start date and vesting one-third on each of the first, second, and third anniversaries of the grant date. The second is a 2026 annual long-term incentive award valued at $1,400,000, prorated from the start date and structured as 50% stock options and 50% RSUs. The filing also states that Bailey will participate in all other elements of the company's executive compensation, benefits plans, and standard severance and change-in-control terms. The Offer Letter was filed as Exhibit 10.1 to the current report.
What Was Disclosed
STAAR Surgical disclosed the appointment of David Bailey as Chief Commercial Officer effective September 8, 2026, and provided the full terms of his compensation, including base salary, bonus eligibility, an initial RSU grant, and a 2026 long-term incentive award.




Please wait processing your request...